Absence of effect of oral rifaximin on the pharmacokinetics of ethinyl estradiol/norgestimate in healthy females

Annals of Pharmacotherapy

Volumn 41, Issue 2, 2007, Pages 222-228

  Trapnell, Carol Braun ^a   Connolly, Margaret ^b   Pentikis, Helen ^a   Forbes, William P ^c,d   Bettenhausen, Doug K ^d  

^a AkaRx Inc   (United States)

^b ICON Development Solutions   (United States)

^c Research and Development

^d Salix a Division of Valeant Pharmaceuticals North America LLC   (United States)

Author keywords

Norgestrel; Pharmacokinetics; Rifaximin

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 3A4; DRUG METABOLITE; ETHINYLESTRADIOL PLUS NORGESTIMATE; NORELGESTROMIN; NORGESTREL; ORAL CONTRACEPTIVE AGENT; RIFAMPICIN; RIFAXIMIN;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; MENSTRUAL IRREGULARITY; NAUSEA; NORMAL HUMAN; NOSE CONGESTION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; VOMITING;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; CONTRACEPTIVES, ORAL, COMBINED; CROSS-OVER STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; ETHINYL ESTRADIOL; FEMALE; HUMANS; MIDDLE AGED; NORGESTREL; RIFAMYCINS; THERAPEUTIC EQUIVALENCY;

EID: 33847342947     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1H395     Document Type: Article

References (17)

1. Adachi JA, DuPont HL. Rifaximin: a novel nonabsorbed rifamycin for gastrointestinal disorders. Clin Infect Dis 2006;42:541-7.
2. Prescribing information. Xifaxan (rifaximin). Morrisville, NC: Salix Pharmaceuticals, June 2004.
3. Descombe JJ, Dubourg D, Picard M, Palazzini E. Pharmacokinetic study of rifaximin after oral administration in healthy volunteers. Int J Clin Pharmacol Res 1994;14:51-6.
4. Rizzello F, Gionchetti P, Venturi A, et al. Rifaximin systemic absorption in patients with ulcerative colitis (letter). Eur J Clin Pharmacol 1998;54:91-3.
5. Gionchetti P, Rizzello F, Ferrieri A, et al. Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: a double-blind, placebo-controlled trial (letter). Dig Dis Sci 1999;44:1220-1.
6. Finch CK, Chrisman CR, Baciewicz AM, Self TH. Rifampin and rifabutin drug interactions: an update. Arch Intern Med 2002;162:985-92.
7. Barditch-Crovo P, Trapnell CB, Ette E, et al. The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive. Clin Pharmacol Ther 1999;65:428-38.
8. Blackburn RD, Cunkelman A, Zlidar VM. Oral contraceptives-an update. Popul Rep A 2000;28:1-16, 25-32.
9. Mosher WD, Martinez GM, Chandra A, Abma JC, Willson SJ. Use of contraception and use of family planning services in the United States: 1982-2002. Adv Data 2004;350:1-36.
10. Guengerich FP. Metabolism of 17 alpha-ethynylestradiol in humans. Life Sci 1990;47:1981-8.
11. Prescribing information. Ortho Tri-Cyclen Tablets and Ortho-Cyclen Tablets (norgestimate/ethinyl estradiol). Raritan, NJ: Ortho-McNeil Pharmaceutical, March 2001.
12. Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Marcel Dekker, 1982:409.
13. Guidance for industry: bioavailability and bioequivalence studies for orally administered drug products-general considerations. In: US Department of Health and Human Service, Food and Drug Administration, CDER, 2003:23.
14. Trapnell CB, Donahue SR, Collins JM, Flockhart DA, Thacker D, Abernethy DR. Thalidomide does not alter the pharmacokinetics of ethinyl estradiol and norethindrone. Clin Pharmacol Ther 1998;64:597-602.
15. Gionchetti P, Rizzello F, Venturi A, et al. Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis. Aliment Pharmacol Ther 1999;13:713-8.
16. Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivisto KT. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet 2003;42:819-50.
17. King A, Laurie R, Connolly M, et al. The effect of rifaximin on the pharmacokinetics (PK) of single doses of intravenous (IV) and oral (PO) midazolam in healthy volunteers (abstract). Clinical Pharmacol Ther 2004;75:P66.